title: Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma.
abstract: In order to identify new serum markers of esophageal squamous cell carcinoma (SCC), we performed serological identification of antigens by recombinant cDNA expression cloning (SEREX). E. coli was transformed with a lambdaZAPII phage cDNA library prepared from mRNA of an esophageal cancer cell line (T.Tn), and IPTG-induced cDNA products were screened for interaction with antibodies in allogeneic sera of patients with esophageal SCC. We identified myomegalin (MMGL, phosphodiesterase 4D interacting protein/PDE4DIP) as a new SEREX antigen for esophageal SCC. Western blot analysis revealed that serum anti-myomegalin antibodies (s-MMGL-Abs) were present in 43 (47%) of 91 patients, but in only one (2.2%) of 45 healthy controls. Of the 21 patients with stage I disease, 8 (38%) were sero-positive. The positive rate of s-MMGL-Abs was greater than those of other conventional tumor markers. Reverse transcription-PCR analysis suggested that alternative splicing from myomegalin variant 1 to variant 5 may explain, in part, the development of s-MMGL-Abs. Although the presence of s-MMGL-Abs was not related to any clinicopathological features of the patients, multivariate analysis indicated that the presence of s-MMGL-Abs was significantly associated with a favorable prognosis. Consequently, s-MMGL-Abs may be a useful tumor marker to diagnose and establish a prognosis in patients with esophageal SCC.
authors.affiliation: Department of Frontier Surgery, Chiba University, Graduate School of Medicine, Chiba 260-8670, Japan.
authors.forename: Hideaki
authors.initials: H
authors.lastname: Shimada
authors.forename: Mari
authors.initials: M
authors.lastname: Kuboshima
authors.forename: Tooru
authors.initials: T
authors.lastname: Shiratori
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Nabeya
authors.forename: Atsushi
authors.initials: A
authors.lastname: Takeuchi
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Takagi
authors.forename: Fumio
authors.initials: F
authors.lastname: Nomura
authors.forename: Masaki
authors.initials: M
authors.lastname: Takiguchi
authors.forename: Takenori
authors.initials: T
authors.lastname: Ochiai
authors.forename: Takaki
authors.initials: T
authors.lastname: Hiwasa
mesh_terms: D000368:Aged; D001323:Autoantibodies / Q000097:blood*; D014408:Biomarkers, Tumor / Q000276:immunology; D015153:Blotting, Western; D002294:Carcinoma, Squamous Cell / Q000235:genetics / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D017931:DNA Primers; D018076:DNA, Complementary / Q000235:genetics; D004938:Esophageal Neoplasms / Q000235:genetics / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008869:Microtubule-Associated Proteins / Q000097:blood / Q000235:genetics* / Q000276:immunology; D008875:Middle Aged; D020133:Reverse Transcriptase Polymerase Chain Reaction; D016019:Survival Analysis
chemical_list: D001323:Autoantibodies; D014408:Biomarkers, Tumor; D017931:DNA Primers; D018076:DNA, Complementary; D008869:Microtubule-Associated Proteins; C426025:Pde4dip protein, rat